文献速递造血干细胞移植与细胞治疗

静息人NK细胞低密度PD-1表达具有功能且在移植后上调

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

研究通过商业克隆和新型抗PD-1试剂检测健康个体及异基因造血干细胞移植(allo-HSCT)后早期重建NK细胞的PD-1表达。发现静息NK细胞存在低而一致的基线PD-1表达,allo-HSCT后配对静息NK细胞PD-1表达增加。 Pembrolizumab阻断未增强NK功能,但其scFv衍生物阻断使脱颗粒增加两倍、细胞因子产生增加至四倍。

要点

  • 静息人NK细胞表达低水平但功能性的PD-1。
  • allo-HSCT后早期重建静息NK细胞PD-1表达上调。
  • scFv衍生物阻断PD-1可增强NK细胞抗肿瘤功能。

核心结论

  • 人NK细胞PD-1/PD-L1轴具有功能重要性,阻断或激活以克服抑制将增强NK细胞介导的抗肿瘤控制。

研究设计与样本

  • 研究检测健康个体和allo-HSCT受者外周血样本,使用商业抗PD-1克隆PD1.3.1.3、FITC标记pembrolizumab或由其制成的FITC标记scFv试剂染色PD-1表达。

主要发现

  • 试剂识别出静息NK细胞上低而一致的基线PD-1表达,且分选NK细胞中PD-1转录本低于静息或活化T细胞。
  • allo-HSCT后配对静息NK细胞PD-1表达增加。
  • pembrolizumab阻断健康供者静息NK细胞PD-1未增强对PD-L1表达肿瘤系的NK功能。
  • scFv衍生物阻断使NK细胞脱颗粒增加两倍、细胞因子产生增加至四倍。
  • PD-L1过表达K562靶细胞抑制NK细胞功能;IL-15活性强且不能被PD-1阻断进一步增强。

临床怎么用

  • PD-1/PD-L1轴阻断可能通过增强NK细胞功能改善抗肿瘤控制,尤其allo-HSCT后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Expression of programmed cell death protein 1 (PD-1) on natural killer (NK) cells has been difficult to analyze on human NK cells. By testing commercial clones and novel anti-PD-1 reagents, we found expression of functional PD-1 on resting human NK cells in healthy individuals and reconstituting NK cells early after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Peripheral blood samples from healthy individuals and transplant recipients were stained for PD-1 expression using the commercial anti-PD-1 clone PD1.3.1.3, fluorescein isothiocyanate (FITC)-labeled pembrolizumab, or an FITC-labeled single-chain variable fragment (scFv) reagent made from pembrolizumab. These reagents identified low yet consistent basal PD-1 expression on resting NK cells, a finding verified by finding lower PD-1 transcripts in sorted NK cells compared with those in resting or activated T cells. An increase in PD-1 expression was identified on paired resting NK cells after allo-HSCT. Blockade of PD-1 on resting NK cells from healthy donors with pembrolizumab did not enhance NK function against programmed death-ligand 1 (PD-L1)-expressing tumor lines, but blocking with its scFv derivative resulted in a twofold increase in NK cell degranulation and up to a fourfold increase in cytokine production. In support of this mechanism, PD-L1 overexpression of K562 targets suppressed NK cell function. Interleukin-15 (IL-15) activity was potent and could not be further enhanced by PD-1 blockade. A similar increase in function was observed with scFv PD-1 blockade on resting blood NK cells after allo-HSCT. We identify the functional importance of the PD-1/PD-L1 axis on human NK cells in which blockade or activation to overcome inhibition will enhance NK cell-mediated antitumor control.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Davis Z, Felices M, Lenvik T, et al. Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Adv. 2021. PMID: 33599743. doi:10.1182/bloodadvances.2019001110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。